Zynerba Pharmaceuticals stock up 52% on positive results in study of fragile X syndrome

Zynerba (NASDAQ: ZYNE) a clinical stage specialty pharma company focused on transdermal cannabinoid treatments, today announced positive results for an open label exploratory Phase 2 trial evaluating ZYN002 cannabinidiol gel in children with Fragile X Syndrome.

The test met its primary endpoint, achieving 46% improvement in the total score of Anxiety, Depression and Mood Scale (ADAMS) at week twelve compared to baseline.

ZYN002 also achieved clinically meaningtful improvements in all measures of the Aberrant Behavior Checklist for Fragile X, which addresses key symptoms including social avoidance, temper tantrums, repetitive movements, and hyperactivity.

The data is “very exciting and demonstrate that ZYN002 may have a profound effect on improving many of the disabling symptoms of Fragile X, such as anxiety and difficult behaviors,” said Steven Siegal, MD, PhD and Chair, at Keck School of Medicine at USC. “ Many families struggle with a lack of approved drugs…” for this disease.

Zynerba expects to move on to Phase 2/3 with adolescent patients in 2018. The FDA has granted Zynerba Orphan Drug designation, which gives it exclusive marketing rights for drugs with less than 200,000 patients for 7 years.

Zynerba stock shot up 52% on the news, on volume of 13 million shares, to close at $9.44. The company’s market cap is $125.15 million.

Source: Zynerba press release

Zynerba Pharmaceuticals stock up 52% on positive results in study of fragile X syndrome

About Cannin: Your Cannabis Stocks Resource

Cannin is your #1 trusted resource for cannabis stocks. Our global team of experts evaluates all emerging cannabis stock investing opportunities. We aggregate hundreds of hours of financial research and provide tips on the best cannabis stocks for 2020.

Use Cannin as your resource for:

Market analysts expect the marijuana and hemp industry will have an annual value exceeding $75 Billion in the next decade. Is it too late to invest in marijuana stocks? No! This is the perfect time to invest.

Are you looking to buy stock in hemp companies or marijuana companies for 2020? Interested in new penny hemp stock companies? Looking for the best Canadian cannabis stocks to invest in? Looking to leverage the power of algorithmic stock trading to beat the cannabis market? We can help.

Are you interested in cannabis stocks like Curaleaf, Trulieve, Aurora Cannabis, Charlotte’s Web, Canopy Growth, or Hemp Inc.?

Predict price movements of cannabis stocks several hours in advance with our proprietary algorithmic stock trading software.

+25% Gains in 2020
+49.8% Gains in 2019
Backtested since 2012

We’re so confident you’ll love our algotrading cannabis stock signals, we’re willing to give you a one-month risk-free trial to see it for yourself.

Profit from the best cannabis stocks – we’ll show you how at cannin.com.

Marijuana Stocks, Pot Stocks, Algorithmic Stock Trading, Hemp stocks

Zynerba Pharmaceuticals stock up 52% on positive results in study of fragile X syndrome